Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial

BACKGROUND: In the INBUILD trial in patients with progressive fibrosing interstitial lung diseases (ILDs), nintedanib reduced the rate of decline in forced vital capacity compared with placebo, with side-effects that were manageable for most patients. We used data from the INBUILD trial to character...

Descripción completa

Detalles Bibliográficos
Autores principales: Cottin, Vincent, Martinez, Fernando J., Jenkins, R. Gisli, Belperio, John A., Kitamura, Hideya, Molina-Molina, Maria, Tschoepe, Inga, Coeck, Carl, Lievens, Dirk, Costabel, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991727/
https://www.ncbi.nlm.nih.gov/pubmed/35392908
http://dx.doi.org/10.1186/s12931-022-01974-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991727/
https://www.ncbi.nlm.nih.gov/pubmed/35392908
http://dx.doi.org/10.1186/s12931-022-01974-2

Ejemplares similares